Paul S Hoffman

Title: Innovations in Antimicrobial Research by Paul S. Hoffman

Introduction

Paul S. Hoffman is an accomplished inventor based in Charlottesville, VA. He has made significant contributions to the field of antimicrobial research, holding a total of 3 patents. His work focuses on developing novel chemical entities that target various human pathogens, showcasing his commitment to advancing medical science.

Latest Patents

Hoffman's latest patents include groundbreaking inventions such as "Broad spectrum benzothiophene-nitrothiazolide and other antimicrobials." This invention provides novel antimicrobial chemical entities based on a nitrothiazolide backbone that exhibit antibacterial and antiparasitic action against a wide range of human pathogens. The new classes of compounds show extended action against Gram-positive bacteria, including MRSA drug-resistant pathogens. In Gram-positive organisms, they specifically target and functionally inhibit microbial attachment to surfaces and biofilm formation. In Gram-negative bacteria, these compounds function as pilicides by inhibiting the assembly of pilin subunits into adhesive filaments. Several of these compounds show potent antimicrobial action against Gram-positive bacteria, potentially involving novel targets. Many of the benzothiophene derivatives exhibit antimicrobial activity in the low micrograms per ml range and block biofilm formation in the nanomolar range, which is well within the range of utility as therapeutics.

Another significant patent is for "Compositions and methods for treating tuberculosis." This invention provides for the use of antimicrobial chemical entities based on a nitrothiazolide backbone that exhibit anti-mycobacteria activity, including the bacteria causing tuberculosis. Multiple compounds were synthesized and screened for anti-tuberculosis activity, resulting in a series of compounds with anti-tuberculosis activity, including six leads that completely inhibited bacterial growth at 5 micrograms per ml or less. Three of these compounds were tested to determine MIC, ranging between 1 and 4 micrograms per ml against both drug-susceptible strains and multi-drug resistant (MDR) strains, including XDR strains. The compounds developed are derived from the parent compound nitazoxanide, which had no inhibitory activity in the stringent testing format used. Many of these compounds have broad-spectrum activity against Gram-positive bacteria, including MRSA, and several lead compounds were not toxic for mice at 200 mg/Kg doses administered over three days.

Career Highlights

Paul S. Hoffman is